# Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

> **NCT03244644** · PHASE3 · COMPLETED · sponsor: **Rebiotix Inc.** · enrollment: 320 (actual)

## Conditions studied

- Clostridium Difficile Infection (CDI)

## Interventions

- **DRUG:** RBX2660
- **DRUG:** Placebo
- **DRUG:** Open label RBX2660 (only for confirmed CDI recurrence)

## Key facts

- **NCT ID:** NCT03244644
- **Lead sponsor:** Rebiotix Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-08-03
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244644, "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03244644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*